Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4298445 · 1 trial · 3 indications
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4298445 (Part A1) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4298445 administered subcutaneously (SC) or intravenously (IV) in healthy participants |
| LY4298445 Placebo (Part A1) | PLACEBO_COMPARATOR | SAD of LY4298445 administered SC or IV in healthy participants |
| LY4298445 (Part A2) | EXPERIMENTAL | SAD of LY4298445 administered SC in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) |
| LY4298445 (Part B) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4298445 administered SC in participants with SLE or RA |
| LY4298445 (Part C) | EXPERIMENTAL | Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants |
| LY4298445 Placebo (Part C) | PLACEBO_COMPARATOR | Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants |
| Name | Type | Description |
|---|---|---|
| LY4298445 | DRUG | Administered SC |
Inclusion Criteria: Healthy Participants Healthy participants between the ages of 18 and 55 years. * Have body weight of at least 50 kilograms (kg) and body mass index (BMI) between 18 and 32 kilogram per square meter (kg/m²), inclusive. Participants with Systemic Lupus Erythematosus (SLE) * Are...
Top 20 of 34 competitors
LY4298445 is an investigational small molecule being developed by Eli Lilly and Company for systemic lupus erythematosus, an autoimmune disease. It is in Phase 1 clinical development and has not been approved by the FDA. Lilly is also studying it in rheumatoid arthritis and healthy participants.
LY4298445 is being evaluated as a potential treatment for systemic lupus erythematosus, an autoimmune condition. It is investigational and has not been approved for any indication. The Phase 1 program also includes participants with rheumatoid arthritis and healthy volunteers, so its use in lupus remains under study.
LY4298445 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the compound in healthy participants and in participants with systemic lupus erythematosus or rheumatoid arthritis.
LY4298445 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The single Phase 1 trial is currently recruiting and is designed to enroll 68 participants, including healthy volunteers and people with systemic lupus erythematosus or rheumatoid arthritis.
LY4298445 is being studied in one Phase 1 trial, NCT07276958, titled A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis. The trial is recruiting, is placebo controlled and randomized, and plans to enroll 68 participants across Australia, China, and Japan.
Yes. The Phase 1 trial NCT07276958 enrolls healthy volunteers alongside participants with systemic lupus erythematosus or rheumatoid arthritis. It is a randomized, placebo-controlled study of 68 participants, open to adults 18 years and older of any sex, and is recruiting in Australia, China, and Japan.